Riskpilot← Back to searchSign inGet full accessTHERADEX ONCOLOGY AB
ABActiveOrg 5592385768Bigatan 9Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201 employees
Revenue 2025
SEK 1,7M
-17% vs 2024
EBITDA margin
-0.4%
-102% vs 2024
Equity ratio
1.3%
Financial strength
Net profit 2025
SEK 1,4M
+328% vs 2024
| Revenue | SEK 1,7M | -17% |
| EBITDA | SEK -7K | -102% |
| Net profit | SEK 1,4M | +328% |
| Total assets | SEK 137,6M | +5394% |
| Equity | SEK 1,8M | +387% |
| Employees | 1 | — |
Legal name
THERADEX ONCOLOGY AB
Org number
5592385768
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 januari 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att bedriva klinisk pröningsledning och därtill förenlig värdepappersverksamhet.
Address
Bigatan 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | −0 | 2 382 | 2 090 | 1 739 |
| Staff expenses | — | −756 | −2 239 | −1 858 | −1 582 |
| EBITDA | −1 932 | −789 | −75 | 336 | −7 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −1 932 | −789 | −75 | 336 | −7 |
| Net financials | — | −0 | −0 | 0 | 1 446 |
| Profit before tax | −1 933 | −789 | −76 | 336 | 1 439 |
| Tax | −0 | — | — | — | — |
| Net profit | −1 933 | −789 | −76 | 336 | 1 439 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 256 | 226 | 1 747 | 2 504 | 137 567 |
| Equity | 25 | 111 | 36 | 372 | 1 811 |
| Long-term debt | 0 | — | 1 415 | 1 757 | 135 352 |
| Short-term debt | 231 | 115 | 297 | 375 | 404 |
| Total debt | 231 | 115 | 1 712 | 2 132 | 135 756 |
EBITDA margin
-0.4%
This company
15.8%
Market median
-103% vs market
20212025
Equity ratio
1.3%
This company
38.2%
Market median
-97% vs market
20212025
Return on equity
79.5%
This company
18.4%
Market median
+332% vs market
20212025
Net profit margin
82.8%
This company
8.1%
Market median
+922% vs market
20212025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20212025
Debt / equity
74.95×
This company
0.62×
Market median
-11989% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-01-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Former (4) | ||
| Chairman | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of THERADEX ONCOLOGY AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Lena Carina Rosén | Deputy Board Member | 0 companies |
| Jack Joachim Emanuel Gullbo | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Hans Edvard Rosén | Chairman | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |